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Abstract 
This article reports on the sixth scientific workshop of the European Crohn’s and Colitis 
Organisation [ECCO] on the pathogenesis of extraintestinal manifestations [EIMs] in inflammatory 
bowel disease [IBD]. This paper has been drafted by 15 ECCO members and 6 external experts [in 
rheumatology, dermatology, ophthalmology, and immunology] from 10 European countries and 
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Abbreviations: CD, Crohn’s disease; IBD, inﬂammatory bowel disease; TNF, tumour necrosis factor; PSC, primary sclerosing cholangitis.
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the USA. Within the workshop, contributors formed subgroups to address specific areas. Following 
a comprehensive literature search, the supporting text was finalized under the leadership of the 
heads of the working groups before being integrated by the group consensus leaders.
1. Introduction
Up to 50% of IBD patients experience at least one extraintestinal 
manifestation [EIM].1 The pathogenic mechanisms of EIM are not 
clearly deﬁned. Unravelling these pathways has the potential to 
enhance our understanding of the pathogenesis not only of EIMs, 
but also of IBD overall. Deﬁning pathogenic pathways in EIMs is 
challenging due to the lack of consistent criteria for diagnosis and 
the difﬁculty in distinguishing drug-induced extraintestinal patholo-
gies from EIMs. Optimizing treatment may also be problematic. 
For many EIMs, commonly accepted deﬁnitions and high-quality 
evidence supporting different treatment strategies are lacking.2 
Therefore, there is a great need for both basic science studies and 
clinical trials to understand the pathogenesis and determine the opti-
mal treatment for EIMs. The ﬁrst ECCO European Evidence-based 
consensus on EIMs in IBD provided an authoritative guideline for 
the clinical management of EIMs.2 The current article seeks to com-
plement and extend the clinical guideline by identifying frontiers and 
opening questions for clinical research.
2. Definition
In order to standardize systematic inclusion of patients in scientiﬁc 
and clinical studies and align outcome measures to ensure clarity 
across the scientiﬁc literature, widely agreed-upon deﬁnitions of the 
pathology being studied are critical. In order to provide a frame of 
reference for scientiﬁc discourse, the expert panel suggests the fol-
lowing mechanistic deﬁnition of what constitutes an EIM:
“An inﬂammatory pathology in a patient with IBD that 
is located outside the gut and for which the pathogenesis 
is either dependent on extension/translocation of immune 
responses from the intestine, or is an independent inﬂam-
matory event perpetuated by IBD or that shares a com-
mon environmental or genetic predisposition with IBD.”
A wide range of extraintestinal pathologies are associated with 
IBD; however, not all of these would be considered to be true EIMs 
according to the deﬁnition above. The panel proposes that current 
data supports the pathologies listed in the ﬁrst column of Table 1 as 
being true EIMs, with other pathologies classiﬁed as associated auto-
immune conditions or complications of IBD and its treatment. The 
distinction between these categories can be imprecise, and overlap 
likely exists; it is probable that, with future new data, some patholo-
gies will be reclassiﬁed. For the purpose of this review, the panel 
focused on true EIMs as described by the deﬁnition above.
3. Basic mechanisms of EIM
3.1. Immunological mechanisms
The potentially diverse immune mechanisms that underlie EIMs are 
poorly deﬁned. We discuss two distinct theories that mechanistic-
ally link inﬂammation in the intestine and at other sites. First, EIMs 
arise from an extension of antigen-speciﬁc immune responses from 
the intestine to non-intestinal sites. Second, EIMs are independent 
inﬂammatory events initiated or perpetuated by the presence of IBD 
or by shared genetic or environmental risk factors in the host. These 
mechanisms are not mutually exclusive and may contribute to vary-
ing degrees in different EIMs [Figure 1].
3.2. Extension of immune responses from the 
intestine
3.2.1. Ectopic expression of gut-specific chemokines and 
adhesion molecules
Abnormal patterns of lymphocyte homing in IBD may contribute 
to EIMs.3 Expression of the vascular addressin MAdCAM-1 is nor-
mally restricted to intestinal tissue and, in the context of speciﬁc 
chemokine signals, enables gut tropic T cells that express α4β7 integ-
rin to trafﬁc selectively to the intestinal mucosa. Additional tropism 
for the small intestine comes from the chemokine CCL25, attract-
ing lymphocytes expressing its receptor CCR9. Ectopic expression 
of both chemokines and adhesion molecules can occur in IBD,4 and 
may facilitate trafﬁcking of inﬂammatory T cells to extraintesti-
nal sites. The best supporting evidence comes from IBD-associated 
primary sclerosing cholangitis [PSC]. Ectopic expression of both 
MAdCAM-1 and CCL25 has been demonstrated in the vascular 
endothelium of the portal tract.5,6 One-ﬁfth of the inﬁltrating T cells 
co-express CCR9 and α4β7, whereas the frequency of these cells is 
low in other forms of liver inﬂammation, indicating an important 
role for these molecules in recruitment of inﬂammatory lymphocytes 
in PSC.6 While it is attractive to propose ectopic expression of gut-
associated addressins at extraintestinal sites as a logical mechanism 
for EIMs, evidence that this occurs in organs other than the liver is 
lacking. However, co-expression of α4β7 with cutaneous leukocyte 
antigen [CLA], [implicated in homing to the skin], by some blood 
T cells from IBD patients,7 may indicate that gut-generated effector 
cells can acquire both gut and skin tropism.
3.2.2. T cell trafficking driven by non-specific adhesion molecules
Upregulation of inﬂammation-associated adhesion molecules and 
chemokines that lack tissue restriction may also enable capture of 
effector cells, facilitating their recruitment into non-intestinal sites. 
Gut leukocytes from IBD patients are able to bind to the synovial 
membrane, using a repertoire of adhesion molecules,8 but mainly 
using endothelial vascular adhesion protein 1 [VAP-1].9 VAP-1 also 
plays a role in transmigration of lymphocytes across the hepatic 
endothelium, and its expression is upregulated by inﬂammation.10,11 
T cells from the intestinal mucosa of IBD patients express chemokine 
receptors, such as CXCR3 and CCR5,12,13 which may contribute to 
their ability to enter other tissues. Low-grade inﬂammation, injury, 
or mechanical stress at extraintestinal sites (as implicated in the 
pathogenesis of spondyloarthritis [SpA]14 and pyoderma gangreno-
sum, where this phenomenon is termed pathergy) may nucleate the 
recruitment of gut-generated effector cells and further enhance the 
inﬂammatory process.
3.2.3. Microbial antigen translocation and/or cross-reactivity
Models of EIMs that invoke trafﬁcking of gut effector T cells raise 
the question as to whether this process is dependent on antigen-spe-
ciﬁc reactivation at non-intestinal sites and, if so, what the antigen 
may be. Antigens derived from the gut microbiota are believed to 
be key targets for intestinal effector T cells in IBD, and transport of 
AQ8
AQ9
2 C. R. H. Hedin et al.
Copyedited by: oup
2.5
2.10
2.15
2.20
2.25
2.30
2.35
2.40
2.45
2.50
2.55
2.60
2.65
2.70
2.75
2.80
2.85
2.90
2.95
2.100
2.105
2.110
2.115
2.120
2.122
these antigens to the liver via the portal circulation may activate such 
cells localized here via α4β7–MAdCAM-1 interactions and other 
pathways. The presence of distinct gut microbiota in IBD patients 
with PSC15–17 may suggest speciﬁc bacterial antigens. At other sites, 
cells may be reactivated by cross-reactive components of the resi-
dent microbiota or host antigens. Molecular mimicry, in the form of 
peptide sequences common between enteric bacteria and host MHC 
molecules has been reported,18,19 although the pathologic signiﬁcance 
of this is unclear. In mice, retina-speciﬁc T cells that cause uveitis 
require activation in the gut by a microbiota-dependent signal, most 
likely a cross-reactive bacterial antigen,20 providing evidence for a 
direct link between gut microbiota, recognition of self-antigens, and 
inﬂammation at a non-intestinal site. Indeed, leukocyte trafﬁcking 
between the gut and the eye has been demonstrated in experimental 
models of autoimmune uveitis.21 However, the antigen speciﬁcity of 
T cells responsible for EIMs in humans has never been deﬁned.
3.2.4. Circulating antibodies
Circulating antibodies could extend intestinal immune responses to 
additional sites, and immune complex–mediated inﬂammation has 
been proposed to contribute to certain EIMs.22 Autoantibodies react-
ive to colonic proteins have been identiﬁed in patients with IBD,23,24 
and [using monoclonal antibodies] epitopes shared between human 
colon and tissues such as eyes, joints, skin, and biliary epithelium 
Table 1. Suggested categorisation of extraintestinal conditions that occur in IBD patients, [list of extraintestinal conditions associated with 
IBD adapted from Harbord et al.2].
System A. Extraintestinal manifestations 
[multifocal inﬂammation]
B. Complications of IBD  
and its treatment
C. Associated conditions  
with uncertain mechanism
Joints and bones Spondyloarthritis Metabolic bone disease/ osteoporosis—[drug 
or nutritionally induced]
Non-inﬂammatory arthralgia
Eye Uveitis
Episcleritis
Scleritis
Drug-induced cataracts and other drug-
induced and nutritional eye disease [see 
supplementary Figure 4]
Oral, aural and nasal Oral CD
Orofacial granulomatosis
Metastatic CD
Sensorineural hearing loss
Skin Erythema nodosum
Pyoderma gangrenosum
Sweet syndrome
Metastatic CD
Drug-induced skin disease [e.g. anti-TNF– 
induced psoriasis, DILE]
Drug-induced skin cancer
Drug hypersensitivity
Vitiligo
Psoriasis
Eczema
Epidermolysis bullosa acquisita
Cutaneous polyarteritis nodosa
Hidradenitis suppurativa
Urogenital Metastatic CD Nephrolithiasis
Amyloidosis
Drug-induced tubulo-interstitial nephritis
Hepato-pancreato-biliary PSC Portal vein thrombosis
Hepatic amyloidosis
DILI
Drug-induced pancreatitis
Autoimmune hepatitis
Granulomatous hepatitis
Autoimmune pancreatitis
Neurological Peripheral neuropathy [drug or nutritionally 
induced]
Venous sinus thrombosis
Stroke
Central demyelination
Cardiovascular Ischaemic heart disease
Cerebrovascular accident
Mesenteric ischaemia
Pulmonary Drug-induced lung ﬁbrosis Inﬂammatory bronchial and 
parenchymal lung disease, 
including asthma, bronchiectasis, 
and interstitial pneumonias
Coagulopathy Venous thromboembolism
Endocrine Drug-induced Cushing’s and Addison 
syndromes
Drug-induced diabetes
Type 1 diabetes
Autoimmune thyroid disease
Infection Infections including systemic and local 
secondary to immunosuppression;
septic complications of IBD or surgery
IBD: inﬂammatory bowel disease, CD: Crohn’s disease, DILE: drug-induced lupus erythematosus, PSC: primary sclerosing cholangitis, DILI: drug-induced liver 
injury.
A. For several conditions, there is evidence for a mechanistic link between two pathologies, as described by the deﬁnition put forward in this paper of a ‘true’ 
extraintestinal manifestation [EIM] of IBD. We would propose that these conditions may also be considered multifocal inﬂammation.
B. Other conditions that occur in IBD patients are complications of the disease or its surgical or pharmacological management.
C. Several conditions occur more commonly in IBD patients, but there is lack of evidence for categorizing these as either complications or directly linking 
them mechanistically to IBD. It is likely that, as pathogenic mechanisms are better understood, it may be possible to re-classify some of these conditions as ‘true’ 
EIMs/ multifocal inﬂammation.
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have been identiﬁed.25–27 However, clear evidence of a causative role 
for antibodies or immune complexes in the pathogenesis of EIMs in 
IBD patients is lacking.
3.3. EIMs as independent inflammatory events
3.3.1. A shift in inﬂammatory tone favours the development 
of EIMs
An alternative explanation for EIMs would see them as independent 
inﬂammatory events sharing common genetic28 or environmental29 
risk factors with IBD. The presence of intestinal inﬂammation and/
or microbial dysbiosis in individuals with IBD might further increase 
the risk of developing extraintestinal inﬂammation through modula-
tion of inﬂammatory ‘tone’, impacting on immune functions at other 
sites. Key inﬂammatory mediators, including IL-6, TNFα, IFNγ, and 
VEGF,30 are raised in the serum of IBD patients, as is bacterial LPS,31 
which may promote cytokine production via activation of immune 
cells at non-intestinal sites. Systemic effects, including increases in epi-
thelial permeability32 and upregulation of neutrophil extravasation 
ligands on vascular endothelium, may lower the threshold for immune 
activation at extraintestinal sites. IBD-associated cytokines, such as 
IL-23, which is produced at high levels in CD and UC, can activate 
immune cells resident within the synovial membrane and drive SpA.33
3.3.2. Systemic changes in innate immune function
Exposure of neutrophils to inﬂammatory cytokines or other signals 
can enhance their response upon subsequent activation, a phenom-
enon termed ‘neutrophil priming’.34 Circulating neutrophils show 
morphological evidence of activation in IBD35 and are primed to 
produce increased levels of TNFα and IL-1β.36 In contrast, recruit-
ment of neutrophils to the skin and clearance of subcutaneous bac-
teria is reduced in patients with CD.37 Likewise, changes in circulating 
monocytes38 and macrophages derived from blood monocytes37 have 
been reported in IBD, with reduced inﬂammatory cytokine produc-
tion in response to bacterial stimulation.
3.3.3. Altered haematopoiesis
Changes in circulating immune cells observed in IBD are likely to 
reﬂect altered haematopoiesis in the bone marrow. In mouse models, 
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Figure 1. Potential mechanisms of EIMs. I Extension of immune responses from the intestine A.Ectopic expression of adhesion molecules and chemokines e.g. 
ectopic expression of MAdCAM-1 and CCL25 in the vascular endothelium of the portal tract. B.T cell trafficking driven by non-specific adhesion molecules e.g. 
α4β7-independent binding of leukocytes to the synovial membrane using a repertoire of adhesion molecules. Non-specific interactions may be initiated after 
low-grade inflammation, injury, or mechanical stress C.Microbial antigen translocation e.g. via portal tracts. D.Microbial antigen cross-reactivity e.g. molecular 
mimicry between enteric bacteria and host MHC molecules. E.Circulating antibodies that may bind epitopes shared between human colon and extraintestinal 
tissues. II EIMs as independent inflammatory events F.Shift in inflammatory tone driven by genetic, environmental, or microbial factors or by a systemic increase 
in key inflammatory mediators. G.Systemic changes in innate immune function e.g. neutrophil priming. H.Altered haematopoiesis driven by microbial products, 
intestinal inflammation, systemic inflammatory cytokines, increased gut permeability, changes in the composition or metabolic products of the microbiota. I.Gut 
microbiota drives distant inflammation via microbial products such as LPS, through changes in gut permeability and microbiota-derived metabolites.
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haematopoiesis is inﬂuenced by both microbial products39–43 and the 
presence of intestinal inﬂammation.44,45 In IBD, systemic inﬂammatory 
cytokines, increased permeability of the intestine to microbial products, 
or changes in the composition and metabolic products of the micro-
biota, could all inﬂuence the generation of innate immune cells.46,47
3.3.4. Dysbiosis and gut microbiota
The long-established link between gut infections with enteric patho-
gens such as Salmonella, Campylobacter, Yersinia, and Shigella and 
reactive arthritis is a clear indication that potential pathogenic path-
ways between microbiota in the gut and extraintestinal inﬂamma-
tion exist. Speciﬁc EIMs are associated with gut dysbiosis: Patients 
with SpA have decreased faecal gut microbial diversity and increased 
abundance of Ruminococcus gnavus and the genus Dialister, which 
are positively correlated with disease activity.48,49 Patients with psori-
atic arthritis also exhibit decreased faecal microbial diversity.50 In 
addition, faecal Saccharomyces cerevisiae abundance is decreased in 
patients with psoriasis compared with healthy controls.51
Primary sclerosing cholangitis has also been associated with 
decreased faecal microbial diversity.15,52 One study has suggested 
that IBD patients have similar dysbiosis to IBD-PSC patients.17 
However, a conﬂicting report53 makes it difﬁcult to judge whether 
the risk for developing PSC is driven by speciﬁc microbial factors.17 
There is a paucity of studies determining gut dysbiosis in individu-
als with inﬂammatory eye disease, although one study demonstrated 
differences in gut microbiota between healthy individuals and those 
with age-related macular degeneration,54 and preliminary data sug-
gested the existence of an intraocular microbiota.55
There is a range of potential mechanisms by which gut micro-
biota drive the pathogenesis of EIMs [Box 1].
The ﬁrst four of these hypothesized mechanisms have been included 
in the discussion in the preceding section. However, gut microbiota 
may promote inﬂammation at extraintestinal sites through meta-
bolic activities. Ruminococcus, which is altered in patients with arth-
ritis, could initiate breach of the intestinal barrier through mucin 
degradation.56 In rats, gut microbiota–dependent alterations in bile 
acid deconjugation are associated with altered bile acid proﬁles in 
extraintestinal sites, including kidney, heart, plasma, and liver, dem-
onstrating that gut microbial metabolic functions have the potential 
to inﬂuence immune signalling at distant sites.57 Short-chain fatty 
acids [SCFAs], produced by many gut bacteria, may have meta-
bolic or immunomodulatory effects. In experimental autoimmune 
uveitis, oral administration of SCFAs attenuated uveitis severity 
and was associated with suppression of effector T cell induction.21 
Furthermore, SCFAs have a potential role in modulating T cell traf-
ﬁcking to extraintestinal sites. Finally it has been hypothesized that 
IBD-linked dysbiosis may exert its pathogenic effect during immune 
development.58 This is supported by animal models, with bacterial 
colonization of mice at age 3 weeks resulting in a persistent inﬂam-
matory tone, whereas colonization when aged 1  week did not.59 
Thus, disruption of the acquisition of gut microbiota early in life 
may generate persistent aberrant immune responses, manifested in 
the gut or extraintestinally or both. Indeed, factors that may inﬂu-
ence the process of gut microbiota acquisition in early life, such as 
breastfeeding, have been shown to be protective against the occur-
rence of ankylosing spondylitis [AS].60
Open questions:
1. Are the gut microbiota pathogenic in EIMs [via any of the mech-
anisms mentioned in the text] or are EIMs independent of gut 
microbiota?
2. If microbiota play a role, what is the mechanism?
3. If EIMs are driven by microbiota, are these the same as or different 
from those involved in IBD pathogenesis?
4. Are microbial communities in other parts of the body involved in 
IBD pathogenesis?
3.4. Genetic basis of extraintestinal manifestations
3.4.1. Familial and epidemiological evidence
There is an extensive overlap in genetic risk loci for both IBD and 
EIMs, particularly AS.61 Association studies revealed a concordance 
in EIMs present in 70% of parent–child pairs and in 84% of sibling 
pairs, highlighting the role of genotype62 [or early life environmental 
factors]. In addition, the appearance of one EIM increases the prob-
ability of developing other EIMs.1,63 Further supporting the genetic 
underpinning of EIMs, the CD risk gene NOD2, encoding a pattern 
recognition receptor, has also been associated with sacroiliitis64 and 
uveitis.65 Several HLA genes and HLA-independent loci have been 
associated with the presence of EIMs, and a detailed description can 
be found in the Supplementary Data. The genetic contribution to the 
pathogenesis of EIMs and IBD comprises a combination of overlap-
ping and independent loci, a situation that is consonant with the 
occurrence of EIMs in individuals both with and without evidence of 
gut inﬂammation. However, whether the involved loci all contribute 
to pathology in an EIM-speciﬁc fashion, or whether there are genes 
that liberate inﬂammatory responses from restriction to speciﬁc body 
compartments and thus give rise to EIMs in general, is not known.
Open questions:
1. Are the genes that predispose to speciﬁc EIMs in IBD patients the 
same as the genes that predispose towards the EIM pathology in 
non-IBD patients?
2. Are there genes common to all EIM patients and distinct from 
non-EIM IBD [immune mobility / promiscuity factors]?
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1. Molecular mimicry: similarity between gut micro-
biota and non-microbial epitopes present at the 
extraintestinal site.
2. Microbial communities in the extraintestinal site: 
similarities with pro-inflammatory gut microbiota 
could drive extraintestinal inflammation.
3. Microbial translocation: Microbiota or their compo-
nents are translocated from the gut to the extraintes-
tinal site, [e.g. to the liver via the portal circulation].
4. Soluble microbial-derived factors, e.g. LPS, may be 
released into the circulation and promote inflamma-
tion at extraintestinal sites.
5. Disruption of gut barrier: Specific microbiota, such as 
mucin degraders, may disrupt the gut mucosal bar-
rier, facilitating leakage of cellular or non-cellular fac-
tors into the circulation.
6. Microbiota-derived metabolites, e.g. from the metab-
olism of bile acids and the generation of short-chain 
fatty acids, could alter immune signalling.
7. Acquisition of deleterious microbiota in early life 
could result in altered immune development, which 
in turn could generate a persistent pro-inflammatory 
immune ‘tone’.
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3. Do IBD patients with no EIMs have protective factors, i.e. do 
they have the same genetic risk as EIM patients, but have add-
itional [genetic or environmental] protective factors?
3.5. Animal models of EIMs
Animal models where inﬂammation is manifested at more than one 
anatomical site or bodily system [multifocal inﬂammation] provide 
experimental platforms for dissecting pathogenic pathways of EIMs 
and serve as tools for testing potential therapies. However, only a 
few models manifest multifocal inﬂammation, with colitis–arthritis 
models being the dominant phenotype available.
TNFΔARE mice carry a genetic deletion of TNF AU-rich elements 
[ARE], leading to overexpression of TNF.66 The resulting pheno-
type is CD-like transmural and granulomatous chronic ileitis along 
with SpA-like sacroiliitis, Achilles tendon enthesitis, and peripheral 
arthritis. Paradoxically [given the importance of innate immune 
responses in human IBD], in this model ileitis appeared to be 
dependent on the presence of mature T and/or B cells, as mice with 
TNFΔARE in combination with a RAG–/– background developed only 
arthritis.66 Furthermore, mice with intestinal epithelial cell-speciﬁc 
TNF ARE deletion develop ileitis but not EIMs,67 indicating that 
intestinal inﬂammation per se is not sufﬁcient for induction of arth-
ritis, which is therefore presumably dependent on local TNF pro-
duction in the joint. Ileitis is abrogated in germ-free TNFΔARE68 and 
TNFΔARE/β7–/– mice,69 but the effects of such manipulations on joint 
inﬂammation have not been reported yet. Taken together, in TNFΔARE 
mice, gut and joint inﬂammation likely represent independent phe-
nomena mediated by a common pro-inﬂammatory factor.
HLA-B27 transgenic rats develop SpA and colitis, but also gastritis, 
psoriasis, and epididymitis.70 In the intestinal mucosa, there is increased 
production of pro-inﬂammatory cytokines [IFN-γ, IL-2, IL-1α, IL-1β, 
TNFα, and MIP2], and in addition plasma concentrations of TNFα 
and IL-6 are raised. IL-23 and IL-17A may play important roles, in 
association with HLA-B27 misfolding in the ER and activation of the 
unfolded protein response, leading to downstream inﬂammation.71,72 
Interestingly, in this model, both colitis and arthritis [but not dermatitis 
or epididymitis] are dependent upon the presence of microbiota.73 The 
HLA-B27 model is consistent with a common genetic origin of multi-
organ inﬂammation, but also emphasizes the fact that some but not all 
EIMs are dependent on microbiota. However, when interpreting data 
from germ-free models, it is important to consider that conventionally 
reared mice are not only colonized with microbiota in the gut, but also 
in other organs such as skin, joints, and eye, which may also play a 
role in pathogenesis. More detailed experiments may be required to 
determine the contribution of extraintestinal microbiota communities 
in animal models of inﬂammation.
SKG mice that receive intraperitoneal injections of 1,3-β-glucan 
develop ileitis in association with enthesitis, arthritis, dactylitis, fas-
ciitis, vertebral inﬂammation, and uveitis.74 Treatment with anti-
IL-23 mAbs or genetic deletion of the downstream cytokine IL-17A 
abrogate both ileitis and arthritis.75 Time-course expression studies 
identiﬁed intestinal mucosa as the source of elevated IL-23 pro-
duction.75 Nevertheless, immunological pathways of joint and gut 
inﬂammation in this model are not identical, because IL-22 neutral-
ization reduced the severity of enthesitis but exacerbated ileitis in 
1,3-β-glucan-treated SKG mice.
Animal models: Open questions
1. Could further animal models with intestinal inﬂammation and 
extraintestinal involvement [including sites other than joints] be 
developed?
2. Which common pathways between mucosal and extraintestinal 
inﬂammation are implicated in animal models where both occur?
3. What is the role of microbiota [including faecal transplant] in the 
development of inﬂammation in animal models?
4. Can animal models be used to elucidate the temporal relationship 
between intestinal disease and development of EIMs?
5. How should animal models be used to investigate novel mecha-
nisms and therapies such as neuroimmunomodulation?
3.6. Implications of the therapeutic effect of 
biologics and other treatments for EIMs
Emerging data for the efﬁcacy of biologics for the treatment of 
EIMs may serve to expose underlying pathogenic mechanisms. Most 
evidence is available for anti-TNFα, with good response rates for 
cutaneous manifestations, arthritis, and ocular EIMs. This has impli-
cated TNFα-dependent mechanisms in EIM pathophysiology.69–71,76 
However, anti-TNFα drugs are increasingly recognized as causing 
drug-induced skin lesions, contributing to the burden of skin disease 
in IBD.77,78 The pathogenesis of these lesions remains unclear; block-
ing TNFα may result in an imbalance of cytokines [for example, 
increased IFNα release, which can cause psoriasis],79–81 and TNFα 
inhibition may lead to a reduced accumulation of Th1 and Th17 
cells at the site of inﬂammation, but trigger a compensatory expan-
sion at other locations.82 Female gender and family history of inﬂam-
matory skin disorders were identiﬁed as risk factors, which may also 
indicate a possible genetic predisposition for anti-TNFα–induced 
skin lesions.83
The gut selective mechanism of the integrin α4β7 antibody ved-
olizumab should restrict its activity to the gut, since its counterpart 
MAdCAM1 is not expressed in the human skin.84 The contribution 
of vedolizumab trials to understanding of EIM pathogenesis is com-
plicated, since the evidence of its effect on EIMs appears to be con-
ﬂicting: One case series did not show any positive effect,85 whereas 
a recent analysis from France suggested positive effects on EIMs in 
most cases, but also revealed new onset of arthritis and paradox-
ical skin lesions.86 The pathogenic mechanisms behind these obser-
vations remain elusive.85 It may be speculated that a compensatory 
expansion of T cells at locations other than the gut could explain 
this phenomenon [similar to anti-TNFα–induced lesions]. On the 
other hand, a beneﬁcial effect of vedolizumab on the disease activity 
of EIMs could occur if lymphocytes require the α4β7–MAdCAM1 
interaction to gain access to the gut, where they are activated, fol-
lowed by non-α4β7–dependent entry to extraintestinal sites. There 
is also evidence in animal models that some regulatory T cells 
require α4β7-dependent entry into the gut to be educated before 
expressing their function elsewhere; vedolizumab could theoretically 
interfere with this.87,88 An alternative hypothesis is that α4β7 is dir-
ectly involved in homing to extraintestinal sites as outlined above. 
It remains likely that vedolizumab has the capacity to illuminate 
pathogenic pathways in EIMs.
Data on other biologic agents are limited. So far, no trial has been 
published evaluating the anti-IL12/23 antibody ustekinumab in the 
management of EIMs. Case series suggest it has efﬁcacy in the treat-
ment of anti-TNFα–induced skin lesions89,90; however, development 
of pustular psoriasis has been described.91 Whether ustekinumab is 
effective in the treatment of non–drug-induced EIMs has yet to be 
determined. In contrast to anti-IL12/23 and despite the pathogenic 
role of Th17 cells in the development of colitis, trials with anti-IL-
17A have failed in IBD with even higher adverse rates than placebo.92 
Moreover, in contrast to its efﬁcacy in other inﬂammatory disorders, 
anti-IL-17A can even exacerbate IBD activity,93 which highlights a 
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distinct involvement of the IL-17A pathway in these entities. No data 
on JAK inhibitors is available so far, but upregulation of STAT3 in 
erythema nodosum and pyoderma gangrenosum84 makes a response 
to JAK inhibitors reasonable to predict and sheds light on the pos-
sible involvement of the JAK-STAT pathway in cutaneous EIMs.
Taken together, it is important that clinical trials and observa-
tional studies of biologic agents are designed to optimize the capture 
of data on effects on inﬂammation in systems other than those of the 
disease deﬁned in the primary outcome.
Open questions:
1. How does vedolizumab affect EIMs? Does it have the same effect 
on all EIMs?
2. What is the implication of the overexpression of STAT for the 
prospect of using JAK-inhibitors for treating PG and EN?
3. How will EIM respond to IL12/23 treatment?
4. Clinical Research
Despite the presence of a wide range of EIMs associated with IBD, 
standardized criteria for diagnosis, documentation or monitoring 
are lacking. Thus far, only one randomized controlled trial including 
IBD patients with EIMs has been conducted.94 Here we discuss the 
currently available paradigms and tools for clinical research in three 
of them: Skin, joint, and eye EIMs.
4.1. Diagnosis and monitoring of EIMs
Because the diagnostic and monitoring tools for EIMs have been 
developed within the organ-based specialities, this section is pre-
sented according to an organ-based structure.
4.1.1. Clinical criteria, indexes, and scales
Joint manifestations
IBD-associated joint symptoms may be subdivided into inﬂammatory 
and non-inﬂammatory joint pain, [arthritis and arthralgia, respect-
ively].95,96 Inﬂammatory arthropathies in IBD are the most common 
EIM and belong to the SpA group, with a prevalence of 20–50% 
for axial inﬂammation,97–99 and 5–20% for peripheral arthritis.100,101 
The Assessment of SpondyloArthritis international Society [ASAS] 
developed classiﬁcation criteria for both inﬂammatory axial and 
peripheral joint disease. These criteria are the current standard for 
clinical trials research and have good performance, as tested against 
the rheumatologist’s diagnosis [Supplementary Figures 1 and 2].102–
104 However, limited data evaluate ASAS criteria speciﬁcally in IBD 
patients. In IBD patients with inﬂammatory back pain, ASAS criteria 
have an equivalent sensitivity but lower speciﬁcity compared with 
non-IBD patients.105 This lower speciﬁcity may be due to the inclu-
sion of IBD as one of the ASAS criteria of axial SpA. Alternative clas-
siﬁcation tools such as the Amor classiﬁcation106 and the European 
Spondyloarthropathy Study Group [ESSG] criteria107 also include 
IBD as a criterion, whereas the older Modiﬁed New York classiﬁ-
cation do not.108 Nevertheless, in order to ensure applicability of 
research data to clinical practice, it is advantageous that the deﬁn-
ition of patient groups in clinical trials and research is consistent with 
that used in rheumatology [i.e. ASAS criteria]. Therefore, validation 
of these currently used tools in IBD patients should be carried out.
Monitoring tools for determining response to treatment and disease 
outcomes have also been developed by ASAS. The current gold stand-
ard tool for axial SpA is the Ankylosing Spondylitis Disease Activity 
Score [ASDAS],109 providing both a measurement of disease activity 
that may be followed over time, as well as cut-offs to allow grouping of 
patients into different disease activity states [Supplementary Figure 3]. 
ASDAS includes back pain as one of the criteria. Hence, it is not well-
adapted for use in the 5–20% of IBD patients with peripheral arthritis. 
In response to the lack of validated outcome measures in peripheral 
SpA the authors of one randomized controlled trial of adalimumab in 
patients with non-psoriatic peripheral SpA developed a new outcome 
measure, the Peripheral SpA Response Criteria [PSpARC40] measured 
after 12 weeks of treatment.110 However, this outcome measure has 
not been widely applied, and there is a need to validate the use of these 
tools in patients with multifocal inﬂammation.
Eye manifestations
The most common eye EIMs are episcleritis and anterior uveitis. 
Scleritis and posterior or intermediate uveitis are rarer, but pose a 
greater potential risk to sight. Supplementary Figure 4 summarizes 
some of the more common types of inﬂammatory eye disease, as 
well as some of the ocular complications of IBD and its treatment. 
Episcleritis is usually treated topically with corticosteroids or non-
steroidals. Uveitis may pose a greater diagnostic and therapeutic 
challenge. The SUN [Standardisation of Uveitis Nomenclature] clas-
siﬁcation is internationally acknowledged, and as such research and 
clinical trials in uveitis in IBD patients should follow this system 
[Supplementary Tables  2–7].111,112 SUN classiﬁcation may be used 
both for diagnosis and classiﬁcation of uveitis at presentation, as 
well as for monitoring disease progression. However, it is relevant 
to consider that the SUN classiﬁcation may have limitations, espe-
cially for judging the signiﬁcance of the outcome of clinical interven-
tions. The FDA deﬁnes a signiﬁcant clinical response as a two-step 
change in parameters of the SUN classiﬁcation, but many successful 
therapies do not meet the required two-step improvement [especially 
in vitreous haze]. Furthermore, the SUN classiﬁcation describes 
anterior chamber cells as in unequal steps [0, +0.5, +1, +2, and +3], 
estimated subjectively by the consulting ophthalmologist, which is 
therefore not optimal for quantitative research.
Skin manifestations
Cutaneous manifestations are common in IBD patients113 and include 
ectopic cutaneous IBD in addition to the other categories of patholo-
gies as set out in Table 1. The diagnosis of cutaneous manifestations 
is principally based on clinical examination of the patient due to 
the inherently accessible nature of the skin. In atypical cases, a skin 
biopsy is helpful.114 In skin disorders, such as psoriasis and eczema, 
speciﬁc indexes to objectively measure skin disease extent and 
activity have been developed (e.g. the Psoriasis Area Severity Index 
[PASI]115–117 and the Eczema Area and Severity Index [EASI]).118 
However similar standardized assessment techniques for cutaneous 
EIMs of IBD, such as EN and PG, are lacking. The only randomized 
controlled trial of therapy for an EIM in IBD patients [inﬂiximab 
for PG] employed a primary end point of clinical improvement at 
Week 2, as determined by the clinician and patient’s global assess-
ment of reduction in ulcer size and depth and the degree of under-
mining of the ulcer edge.94 Inﬂiximab was shown to be superior to 
placebo, particularly in patients with disease duration of ≤3 months. 
Standardisation of assessment methods, such as that employed in 
this trial, will enhance reproducibility in clinical research as well as 
facilitating meta-analysis of EIM research.
In summary, current tools for the diagnosis of EIM have for the 
most part been developed in patients with unifocal inﬂammation. 
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Studies to validate the use of these tools in patients with multi-
focal inﬂammation, including IBD patients, are needed. Even better 
would be a system of diagnosis and monitoring that reﬂects common 
pathogenic mechanisms that could then be applied to diseases gener-
ated by that common mechanism but manifesting in diverse clinical 
phenotypes.
Open questions:
1. Are tools for monitoring of unifocal inﬂammation valid for use 
in patients with multifocal inﬂammation?
2. If one of the criteria in an algorithm for diagnosing inﬂammatory 
pathology at an extraintestinal site is that the patient has IBD, will 
such an algorithm provide adequate diagnostic discrimination 
when applied to a population of IBD patients?
3. Is a single multidimensional scale for diagnosis and monitoring 
of inﬂammation at multiple sites possible? Is it desirable?
4.1.2. Biomarkers
There are no speciﬁc biomarkers for EIM activity in IBD, with acute-
phase proteins ESR and CRP, leucocytosis, thrombocytosis, and 
anaemia being non-speciﬁc and, in addition, ESR and CRP having 
low sensitivity being elevated in only 40–50% of patients with axial 
SpA. Conversely, faecal calprotectin is only validated in the diagno-
sis and monitoring of gut inﬂammation and does not reﬂect disease 
activity at other sites.
Genetic markers for SpA
Genetic factors may be utilized as biomarkers in the diagnosis of 
inﬂammatory pathology.119,120 Combining clinical factors with gen-
etic data has been shown to be superior in predicting the develop-
ment of EIMs compared with either alone. HLA-B27–positive IBD 
patients are at increased risk of developing AS.2 Apart from HLA-
B27, over 41 genes have been identiﬁed predisposing to AS.121,122 
However, most of these have not been associated with increased risk 
for extra-articular inﬂammation. Currently there are neither reliable 
genetic biomarkers for peripheral SpA,119,123,124 nor for cutaneous or 
ocular EIMs.
Imaging biomarkers for spondyloarthritis
Traditional X-rays are of value in diagnosing axial SpA, but only 
demonstrate changes in advanced cases. Magnetic resonance 
imaging usually demonstrates the ﬁrst radiological changes in axial 
SpA and is—despite moderate sensitivity and speciﬁcity125—the 
imaging test of choice for detection of early disease,126–128 as well 
as the best objective technique for assessing inﬂammatory disease 
activity.129–134 This assessment has been standardized with the use of 
the Bath Ankylosing Spondylitis Radiology Index [BASRI].135 In per-
ipheral arthritis, which is generally non-erosive, joint radiography is 
usually normal, so ultrasonography is often employed to conﬁrm the 
diagnosis. In addition, there is no evidence to conﬁrm or refute the 
assumption that radiological ﬁndings in inﬂammatory arthropathy 
differ between patients with only arthritis and those who also have 
inﬂammation at distal sites.
Antimicrobial antibodies
IBD is associated with the presence of antibodies to a variety of 
microorganisms, such as anti-Saccharomyces cerevesiae antibod-
ies [ASCA], antineutrophil cytoplasmic antibodies [ANCA], anti-I2 
[associated with anti-Pseudomonas activity], anti-Escherichia coli 
outer membrane porin C [anti-OmpC], and anti-ﬂagellin antibodies 
[anti-CBir1]. Subclinical intestinal inﬂammation has been reported 
to be present in a signiﬁcant proportion of patients with radio-
graphic axial SpA.136,137 The data on the presence of these antimicro-
bial antibodies in patients with both IBD and SpA are inconsistent 
and mostly relate to axial SpA. Anti-I2 antibodies have been associ-
ated with the combination of AS and intestinal inﬂammation,137 as 
have antibodies against ASCA, anti-OmpC, and anti-CBir1.138
Open questions:
1. Should patients presenting with inﬂammatory pathologies be 
screened for multifocal inﬂammation?
2. Which biomarkers would be most appropriate for screening and in 
which populations?
3. Would biomarkers be useful for guiding therapeutic decisions, 
even in patients with unifocal inﬂammation [to reveal underlying 
mechanisms]?
4.2. Predictors and treatment of EIMs
4.2.1. Predictors of EIMs
The identiﬁcation of patients at risk of EIMs is desirable, because 
this raises the possibility not only of treatment initiation prior to 
permanent tissue destruction, but even the potential for disease 
prevention. Moreover, patients in whom a propensity to develop 
inﬂammatory disease has already declared itself in one system may 
provide a unique opportunity for targeted screening in order to 
detect inﬂammation at distant anatomical sites. Several studies have 
investigated factors inﬂuencing the risk of developing EIMs, but with 
inconsistent results. This is likely caused by differences across stud-
ies regarding deﬁnitions and assessment of EIMs as well as patient 
populations, since only very few population-based studies exist. 
Furthermore, the occurrence and risk factors for EIMs may also vary 
geographically.139–141
On the simplest level, demographic and clinical factors may be 
used to detect risk. For example, female sex,29,63,113,142–146 CD rather 
than UC,113,142,143,147,148 increasing age,29,143,149 long disease dur-
ation,142,143 colonic location in CD,100,143 extensive UC compared 
with proctitis,142,147 indicators of severe disease including the need 
for steroids,146 azathioprine,146 biologic therapy,29 or surgery,100,144,148 
and smoking both in CD29,148 and UC29,150 have all been associated 
with an increased risk for EIMs. However, these associations are not 
reported consistently and are not replicated in all population-based 
studies147–149 and, as such, this approach may have limited applic-
ability in clinical practice. Genetic factors play an important role in 
determining the presence of EIMs,119,120 especially genes in the HLA 
region on chromosome 6, as described above.151–153 Combining clin-
ical factors with genetic data has been shown to be superior for pre-
dicting the development of EIMs compared with either alone.119,124 
Furthermore, speciﬁc features of the clinical presentation may alert 
the clinician to the potential for future EIMs. For example, IBD is 
in the differential of any patient with ocular inﬂammation, espe-
cially in the ‘typical’ constellation of bilateral anterior/intermediate 
granulomatous uveitis. Conversely, it is wise to monitor liver func-
tion tests, especially in the IBD patient presenting with the clinical 
picture of mild, extensive colitis with rectal sparing and backwash 
ileitis, often associated with PSC.
Screening for IBD in patients with AS has been studied with some 
success, although the low rate of development of IBD in this group 
made the usefulness of screening somewhat questionable.154 EIMs 
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are often tested for based on clinical suspicion; however, screening 
for secondary diagnoses in patients with inﬂammatory pathologies 
has not yet proved to be a fruitful strategy.
Open questions:
1. Can accurate predictors of EIMs be developed?
2. Once predictors are available: Can early intervention alter the 
future development of EIMs?
4.2.2. Treatment
A recent systematic review by Peyrin-Biroulet et al. based on nine 
interventional studies, seven open-label studies, and thirteen non-
interventional studies found a good clinical efﬁcacy of adalimumab 
and inﬂiximab for the treatment of musculoskeletal, cutaneous, and 
ocular manifestations, and some beneﬁcial effect in metabolic bone 
disease and haematological or vascular EIMs in IBD patients.155 In 
contrast, no or limited efﬁcacy of other biologic drugs, including 
certolizumab pegol, golimumab, vedolizumab, or natalizumab was 
identiﬁed. In this review, however, different ranges of pathology get 
grouped together, which may obscure the therapeutic effect for spe-
ciﬁc types of EIMs that share a common mechanism.
Paradoxically, drug-induced EIMs are well documented and hint at 
the complex effects that interference with immune function may have. 
This complexity is potentially compounded in patients with multi-
focal inﬂammation. The effect of vedolizumab, [which blocks α4β7-
dependent migration of lymphocytes into the gut] on EIMs has been 
difﬁcult to predict, as discussed above. Potentially vedolizumab may 
have no effect on extraintestinal inﬂammation due to its gut-selective 
nature; alternatively if lymphocytes causing extraintestinal inﬂam-
mation require activation in the gut before migration to the distant 
site, then vedolizumab would be predicted to improve EIMs. Finally, 
if prevention of migration to the gut resulted in accumulation of lym-
phocytes at extraintestinal sites, then vedolizumab could cause exacer-
bation of EIMs. Of course, it may be that each of these mechanisms 
is present in different patients. Another treatment strategy that may 
be examined in the future is combination therapy with biologics with 
different molecular targets, for example, combined anti-integrin/anti-
TNFα therapy for IBD patients with EIMs has shown some efﬁcacy.156
It has been hypothesized that the extent of inﬂammation [e.g. 
the size of ulcerations in PG] may determine optimal drug dosing, 
with larger ulcers requiring higher doses of the drug.94 However no 
dose–response studies and no RCTs have been presented in IBD-
EIM patients during the induction phase of anti-TNFα treatment 
to determine optimal trough levels.157 The concept of relating drug 
dose to total inﬂammatory burden has instinctive validity and could 
potentially be of great relevance to patients with EIMs. However, 
this concept remains speculative at present and requires validation 
in clinical trials.158
Open questions:
1. Is there a dose–response relationship between anti-TNFα therapy 
and EIM treatment response?
2. Are all anti-TNFα antibodies equally effective for the treatment of 
EIMs?
3. Is there an additive effect of combined immunosuppression in IBD 
patients with EIM?
4. Are optimal anti-TNFα trough levels for IBD patients with EIMs 
different from those for IBD patients without EIM?
4.3. Treat to target and patient-reported outcome 
measures in EIMs
A ‘treat to target’ strategy has been developed in many areas 
of medicine, in which treatment outcomes are defined by spe-
cific objective end points. The concept driving this strategy is 
that traditional outcome measures fail to reflect subclinical, 
yet active disease, permitting the accumulation of tissue dam-
age over time. With a treat-to-target strategy therapy is intensi-
fied until the relevant evidence-based treatment target is in the 
desired range, which is associated with a reduction in end-organ 
destruction. For example in rheumatoid arthritis, scores such as 
the Disease Activity Score Calculator for Rheumatoid Arthritis 
[DAS-28] have been established.159 This approach has also been 
used successfully in endocrinology, especially in diabetes man-
agement.160–162 Ongoing studies are developing this strategy in 
IBD.163 Whether the same treatment targets developed for uni-
focal inflammation, can be applied [individually or perhaps in 
combination] in IBD-EIMs, or whether different targets should 
be developed, is unclear.
Another current advancement in the care of patients with 
chronic conditions is the development of Patient-Reported Outcome 
Measures [PROMs], which may themselves function as a treat-
ment target. PROMs are deﬁned by the FDA as “any report of the 
status of a patient’s health condition that comes directly from the 
patient, without interpretation of the patient’s response by a clin-
ician or anyone else.”164 PROMs may be disease speciﬁc, such as 
the Inﬂammatory Bowel Disease Questionnaire [IBDQ-32],165 
the Inﬂammatory Bowel Disease Quality of Life Questionnaire 
[IBDQOL],166 or the Work Productivity and Activity Impairment: 
Crohn’s Disease [WPAI: CD].167 The use of PROMs designed for 
the assessment of unifocal inﬂammation in patients with multifocal 
inﬂammation presents obvious drawbacks, potentially missing sig-
niﬁcant aspects of the patient’s experience. However, non-disease–
speciﬁc instruments have been developed, such as the Short-Form 
Health Survey168 and the EQ-5D,169 which may be more applicable 
in multifocal inﬂammation.
Open questions:
1. What are appropriate treatment targets for patients with multi-
focal inﬂammation?
2. Can established treatment targets from patients with joint, skin, or 
eye disease be employed for patients with EIMs in IBD?
3. Would there be a difference in how PROMs and treat-to-target 
strategies function in patients with EIM activity that is synchron-
ous with the IBD activity, compared with patients with asyn-
chronous disease activity?
5. Conclusion
Determining the mechanisms that cause inﬂammation to manifest 
unifocally or multifocally in different patients remains an enticing 
conundrum in immunology. Solving this conundrum may illuminate 
novel mechanisms and reveal a broader range of therapeutic targets. 
In the context of the availability of a greater number of drugs aimed 
toward this broadening range of molecular targets, the previous 
organ-based approach to inﬂammatory disease may be inadequate. 
A holistic approach to the diagnosis and monitoring of inﬂamma-
tory disease will allow a personalized therapeutic strategy. New 
tools for monitoring multifocal inﬂammation are needed in order to 
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better capture the experience of the patient. This holistic approach to 
inﬂammatory disease requires greater cooperation between speciali-
ties and across research disciplines.
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